534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Cortellini, Alessio;Garbo, Edoardo;Brunetti, Leonardo;Di Fazio, Giuseppina Rita;Loza, Monica;Genova, Carlo;Jayakrishnan, Ritujith;Montrone, Michele;Li, Mingjia;Young, Lauren;Metro, Giulio;Passiglia, Francesco;Awosika, Nichola O;Josephides, Eleni;Tomasik, Bartlomiej;Giusti, Raffaele;Bria, Emilio;Rost, Maximilian;Minuti, Gabriele;Mazzoni, Francesca;Aujayeb, Avinash;Morabito, Alessandro;Leonetti, Alessandro;Addeo, Alfredo;Mountzios, Giannis;Kalvapudi, Sukumar;Karapanagiotou, Eleni;Monnet, Isabelle;Piedra, Aida;Agustoni, Francesco;Cortinovis, Diego L;Gorria, Teresa;Beninato, Teresa;Moliner, Laura;Biello, Federica;Hejleh, Taher A;Nassar, Amin;Ricciuti, Biagio

2024-01-01